00867 CMS
- 7.690
- +0.260+3.50%
CMS News
CMS To Go Ex-Dividend On May 13th, 2024 With 0.086 HKD Dividend Per Share
May 9th - $CMS(00867.HK)$ is trading ex-dividend on May 13th, 2024. Shareholders of record on May 14th, 2024 will receive 0.086 HKD dividend per share on May 23rd, 2024. The ex-dividend date is Ma
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up
The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)
Repurchase Collection on April 24 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$82,6392 million
According to HKEx's April 25 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 1,285,200 common shares on April 23, involving an amount of HK$82,6392 million. The repurchase price per share ranged from HK$64.65 to HK$64.05. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 24, involving an amount of HK$597.95 million, with a repurchase price of HK$100.3 per share
Kangzhe Pharmaceutical (00867.HK) spent HK$7.3872 million to buy back 1.05 million shares on April 24
Gelonghui, April 24 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.3872 million to repurchase 1.05 million shares on April 24.
Kangzhe Pharmaceutical (00867.HK): The application for permission to market dexidolastat tablets in China has been accepted
Kangzhe Pharmaceutical (00867.HK) announced that the new drug marketing license application (NDA) for desidustat tablets (former name: dexidostat tablets) was accepted by the China National Drug Administration (NMPA) on April 22, 2024. The product is an innovative oral hypoxia-inducible factor-proline hydroxylase inhibitor (HIF-PHI), intended for the treatment of anemia in non-dialyzed adult patients with chronic kidney disease (CKD).
Repurchase Collection on April 17 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$226 million
According to HKEx's April 18 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.6 million common shares on April 16, involving an amount of HK$226 million. The repurchase price per share ranged from HK$63.05 to HK$62.25. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 17, involving an amount of HK$57.427,600. The repurchase price per share ranged from HK$96.65 to 94.9
Kangzhe Pharmaceutical (00867.HK) spent HK$7.423,800 to buy back 1.06 million shares on April 17
Gelonghui, April 17 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.423,800 to buy back 1.06 million shares on April 17.
康哲藥業：股東週年大會通告
康哲藥業：2023年度報告
China Medical System Registers New Vitiligo Drug in Macau
China Medical System Holdings (HKG:0867) said its Vitiligo drug was registered by Macau's Pharmaceutical Administration Bureau (ISAF), according to a Tuesday filing on the Hong Kong bourse. Ruxolitini
Repurchase Collection on April 15 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$263 million
According to HKEx's April 16 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 4.147,200 common shares on April 12, involving an amount of HK$263 million. The repurchase price per share ranged from HK$63.85 to HK$63.05. ② $Hang Seng Bank (00011.HK) $ repurchased 5992 thousand common shares on April 15, involving an amount of HK$58.728 million, with a repurchase price of HK$99.3 per share
Kangzhe Pharmaceutical (00867.HK) spent HK$7.44 million to buy back 1.05 million shares on April 15
Gelonghui, April 15 | Kangzhe Pharmaceutical (00867.HK) announced that it spent 7.44 million HK$7.44 million to repurchase 1.05 million shares on April 15.
Repurchase Collection on April 12 | Tencent Holdings, HSBC Holdings, etc. have repurchased, of which Tencent Holdings spent HK$1 billion
According to documents disclosed by the Hong Kong Stock Exchange on April 15, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.2 million common shares on April 12, involving an amount of HK$1 billion. The repurchase price per share ranged from HK$317.4 to HK$309.4. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 212 million shares, accounting for 2.211% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (0000
Kangzhe Pharmaceutical (00867.HK) spent HK$7.64 million to buy back 1.05 million shares on April 12
Gelonghui, April 12 | Kangzhe Pharmaceutical (00867.HK) announced that it spent 7.64 million HK$7.64 million to repurchase 1.05 million shares on April 12.
Repurchase Collection on April 11 | Tencent Holdings, HSBC Holdings, etc. have repurchased, of which Tencent Holdings spent HK$1 billion
According to documents disclosed by the Hong Kong Stock Exchange on April 12, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.18 million common shares on April 11, involving an amount of HK$1 billion. The repurchase price per share ranged from HK$316.6 to HK$311.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 209 million shares, accounting for 2.178% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (0000
Kangzhe Pharmaceutical (00867.HK) spent HK$7.993 million to buy back 1.1 million shares on April 11
Gelonghui, April 11 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.993 million to repurchase 1.1 million shares on April 11.
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Repurchase Collection on April 10 | Tencent Holdings, HSBC Holdings, etc. bought back one after another, of which Tencent Holdings spent HK$1,001 billion
According to documents disclosed by the Hong Kong Stock Exchange on April 11, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.2 million common shares on April 10, involving an amount of HK$1,001 billion. The repurchase price for each share ranged from HK$315.2 to HK$307. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 206 million shares, accounting for 2.144% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (000
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Analysis
Price Target
No Data
